• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Blood and Lymphatic Cancer: Targets and Therapy >Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
【24h】

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas

机译：伊达拉西布治疗惰性B细胞恶性肿瘤：慢性淋巴细胞性白血病和小淋巴细胞或滤泡性淋巴瘤

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma are indolent B-cell lymphoproliferative disorders that mainly affect an older population. Although the majority of patients in need of treatment derive significant benefit from conventional chemotherapeutic agents as well as monoclonal antibodies, less toxic and more effective treatments are needed. Novel agents that inhibit the B-cell receptor signaling pathway have shown promising outcomes in these disorders. Idelalisib is a potent selective oral inhibitor of phosphatidylinositol 3-kinase delta and has shown significant clinical activity in B-cell malignancies. In this review, we summarize the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of relapsed/refractory disease. The adverse effect profile includes autoimmune disorders such as transaminitis, colitis, and pneumonitis. Given the efficacy and manageable toxicity profile of idelalisib, it is being increasingly incorporated into the management of indolent B-cell malignancies.
机译：慢性淋巴细胞性白血病，小淋巴细胞性淋巴瘤和滤泡性淋巴瘤是顽固的B细胞淋巴组织增生性疾病，主要影响老年人群。尽管大多数需要治疗的患者都从常规化疗药物以及单克隆抗体中获得了显着的收益，但仍需要毒性更低，更有效的治疗方法。抑制B细胞受体信号传导途径的新型药物在这些疾病中显示出令人鼓舞的结果。依达拉西布是一种有效的选择性口服磷脂酰肌醇3-激酶δ抑制剂，在B细胞恶性肿瘤中显示出显着的临床活性。在这篇综述中，我们总结了使用艾达拉西单药或与利妥昔单抗联合治疗复发/难治性疾病的临床试验数据。不良反应包括自身免疫性疾病，例如转氨炎，结肠炎和肺炎。鉴于艾屈拉西布的功效和可控的毒性特征，它正越来越多地纳入惰性B细胞恶性肿瘤的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号